Hepatitis B screening: Difference between revisions
Joao Silva (talk | contribs) No edit summary |
Joao Silva (talk | contribs) |
||
Line 21: | Line 21: | ||
* [[Coagulation]] studies | * [[Coagulation]] studies | ||
Diagnosis is confirmed by demonstration in sera of specific [[antigens]] and/or [[antibodies]]. Three clinical useful [[antigen]]-[[antibody]] systems have been identified for [[hepatitis B]]: | |||
* Hepatitis B surface antigen ([[HBsAg]]) and antibody to [[HBsAg]] (anti-HBs) | |||
* Antibody (anti-HBc IgM and anti-HBc IgG) to hepatitis B core antigen (HBcAg) | |||
* Hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe) | |||
==Recommendations for Persons Who Should Be Tested for HBV Infection: AASLD Practice Guidelines 2009<ref name="pmid15229781">{{cite journal |author=Lok AS, McMahon BJ |title=[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines] |journal=[[Romanian Journal of Gastroenterology]] |volume=13 |issue=2 |pages=150–4 |year=2004 |month=June |pmid=15229781 |doi= |url=http://www.aasld.org/practiceguidelines/documents/bookmarked%20practice%20guidelines/chronic_hep_b_update_2009%208_24_2009.pdf |accessdate=2012-02-10}}</ref>== | ==Recommendations for Persons Who Should Be Tested for HBV Infection: AASLD Practice Guidelines 2009<ref name="pmid15229781">{{cite journal |author=Lok AS, McMahon BJ |title=[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines] |journal=[[Romanian Journal of Gastroenterology]] |volume=13 |issue=2 |pages=150–4 |year=2004 |month=June |pmid=15229781 |doi= |url=http://www.aasld.org/practiceguidelines/documents/bookmarked%20practice%20guidelines/chronic_hep_b_update_2009%208_24_2009.pdf |accessdate=2012-02-10}}</ref>== |
Revision as of 19:53, 29 July 2014
Hepatitis B |
Diagnosis |
Treatment |
Case Studies |
Hepatitis B screening On the Web |
American Roentgen Ray Society Images of Hepatitis B screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Screening
Large-scale screening for HBV infection
Diagnosis of hepatitis is made by biochemical assessment of liver function. Initial laboratory evaluation should include:[1][2]
- Total and direct bilirubin
- ALT
- AST
- Alkaline phosphatase
- Prothrombin time
- Total protein
- Albumin
- Globulin
- Complete blood count
- Coagulation studies
Diagnosis is confirmed by demonstration in sera of specific antigens and/or antibodies. Three clinical useful antigen-antibody systems have been identified for hepatitis B:
- Hepatitis B surface antigen (HBsAg) and antibody to HBsAg (anti-HBs)
- Antibody (anti-HBc IgM and anti-HBc IgG) to hepatitis B core antigen (HBcAg)
- Hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe)
Recommendations for Persons Who Should Be Tested for HBV Infection: AASLD Practice Guidelines 2009[3]
“ | The following groups should be tested for HBV
infection:
|
” |
Recommendations for HCC Screening: AASLD Practice Guidelines 2009[3]
“ |
1. HBV carriers at high risk for HCC such as Asian men over 40 years and Asian women over 50 years of age, persons with cirrhosis, persons with a family history of HCC, Africans over 20 years of age, and any carrier over 40 years with persistent or intermittent ALT elevation and/or high HBV DNA level >2,000 IU/mL should be screened with US examination every 6-12 months. (Grade II-2) 2. For HBV carriers at high risk for HCC who are living in areas where US is not readily available, periodic screening with AFP should be considered. (Grade II-2) |
” |
References
- ↑ "Hepatitis B" (PDF).
- ↑ Fields, Bernard (2007). Fields virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. ISBN 0781760607.
- ↑ 3.0 3.1 Lok AS, McMahon BJ (2004). "[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines]" (PDF). Romanian Journal of Gastroenterology. 13 (2): 150–4. PMID 15229781. Retrieved 2012-02-10. Unknown parameter
|month=
ignored (help)